RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate summary
and update regarding the Company's clinical programs at the following
investor conferences:
-
Jefferies Global Healthcare Conference in New York on Thursday, June
9, 2011 at 11 a.m. Eastern time
-
Wells Fargo Healthcare Conference in Boston on Thursday, June 23, 2011
at 1:30 p.m. Eastern Time
Links to live audio webcasts and replays of both presentations may be
accessed on the BioCryst website at www.BioCryst.com.
About BioCryst
BioCryst Pharmaceuticals designs, optimizes and develops novel
small-molecule pharmaceuticals that block key enzymes involved in
infectious diseases, inflammatory diseases and cancer. BioCryst
currently has three novel late-stage compounds in development: peramivir,
a neuraminidase inhibitor for the treatment of influenza, BCX4208,
a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of
gout, and forodesine, an orally-available PNP inhibitor for
hematological malignancies. Utilizing crystallography and structure-based
drug design, BioCryst continues to discover additional compounds and
to progress others through pre-clinical and early development to address
the unmet medical needs of patients and physicians. For more
information, please visit the Company's website at www.biocryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
BioCryst Pharmaceuticals
Robert Bennett, 919-859-7910
Source: BioCryst Pharmaceuticals, Inc.
News Provided by Acquire Media